Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Evaluating perioperative apalutamide and ADT with surgery in prostate cancer

Alberto Briganti • 24 Oct 2026
ESMO 2026
Genitourinary Cancer Prostate Cancer Apalutamide
PROTEUS

Alberto Briganti, MD, Vita-Salute University San Raffaele, Milan, Italy, discusses the PROTEUS substudy (NCT03767244), which found that the use of apalutamide plus androgen deprivation therapy (ADT) nearly halved the need for subsequent therapies, including hormonal manipulation or radiation therapy, after radical prostatectomy. This treatment regimen may delay the use of subsequent therapies by approximately three years, potentially reducing treatment toxicity. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alberto Briganti

Impact of perioperative treatment on prostate cancer in the PROTEUS trial
1:07
Impact of perioperative treatment on prostate cancer in the PROTEUS trial
Alberto Briganti • 24 Oct 2026
PROTEUS: substudy data of perioperative apalutamide and ADT and surgery
1:48
PROTEUS: substudy data of perioperative apalutamide and ADT and surgery
Alberto Briganti • 24 Oct 2026

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals